Intermittent morphine treatment causes a protracted increase in cholinergic striatal neurotransmission measured ex vivo

Anton N.M. Schoffelmeer, Patrizia Nestby, Guno H.K. Tjon, George Wardeh, Taco J. De Vries, Louk J.M.J. Vanderschuren, Arie H. Mulder

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Considering the long-lasting neuroadaptations that occur in the brain after exposure to drugs of abuse, we found that the facilitatory effect of an EC50 concentration (0.1 μM) of the acetylcholinesterase inhibitor physostigmine, unlike that of the muscarinic receptor agonist oxotremorine, on K+-induced [3H]dopamine release from rat striatal slices was enhanced about 2-fold 1 month after cessation of intermittent morphine treatment. Similarly, the inhibitory effect of physostigmine on K+-induced [14C]acetylcholine release from the slices was enhanced subsequent to morphine treatment, whereas that of oxotremorine appeared to be unchanged. Therefore, intermittent morphine administration may cause a very long-lasting increase of muscarinic receptor activation by released endogenous acetylcholine in rat striatum, which may play a pivotal role in the enduring character of stimulus hyperresponsiveness after exposure to drugs of abuse.

Original languageEnglish
Pages (from-to)311-314
Number of pages4
JournalEuropean Journal of Pharmacology
Volume286
Issue number3
DOIs
Publication statusPublished - 24 Nov 1995

Cite this

Schoffelmeer, Anton N.M. ; Nestby, Patrizia ; Tjon, Guno H.K. ; Wardeh, George ; De Vries, Taco J. ; Vanderschuren, Louk J.M.J. ; Mulder, Arie H. / Intermittent morphine treatment causes a protracted increase in cholinergic striatal neurotransmission measured ex vivo. In: European Journal of Pharmacology. 1995 ; Vol. 286, No. 3. pp. 311-314.
@article{8975ef14cbe44010bcf070b200faad03,
title = "Intermittent morphine treatment causes a protracted increase in cholinergic striatal neurotransmission measured ex vivo",
abstract = "Considering the long-lasting neuroadaptations that occur in the brain after exposure to drugs of abuse, we found that the facilitatory effect of an EC50 concentration (0.1 μM) of the acetylcholinesterase inhibitor physostigmine, unlike that of the muscarinic receptor agonist oxotremorine, on K+-induced [3H]dopamine release from rat striatal slices was enhanced about 2-fold 1 month after cessation of intermittent morphine treatment. Similarly, the inhibitory effect of physostigmine on K+-induced [14C]acetylcholine release from the slices was enhanced subsequent to morphine treatment, whereas that of oxotremorine appeared to be unchanged. Therefore, intermittent morphine administration may cause a very long-lasting increase of muscarinic receptor activation by released endogenous acetylcholine in rat striatum, which may play a pivotal role in the enduring character of stimulus hyperresponsiveness after exposure to drugs of abuse.",
keywords = "Acetylcholine, Morphine, Muscarinic receptor, Striatum",
author = "Schoffelmeer, {Anton N.M.} and Patrizia Nestby and Tjon, {Guno H.K.} and George Wardeh and {De Vries}, {Taco J.} and Vanderschuren, {Louk J.M.J.} and Mulder, {Arie H.}",
year = "1995",
month = "11",
day = "24",
doi = "10.1016/0014-2999(95)00588-7",
language = "English",
volume = "286",
pages = "311--314",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "3",

}

Intermittent morphine treatment causes a protracted increase in cholinergic striatal neurotransmission measured ex vivo. / Schoffelmeer, Anton N.M.; Nestby, Patrizia; Tjon, Guno H.K.; Wardeh, George; De Vries, Taco J.; Vanderschuren, Louk J.M.J.; Mulder, Arie H.

In: European Journal of Pharmacology, Vol. 286, No. 3, 24.11.1995, p. 311-314.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Intermittent morphine treatment causes a protracted increase in cholinergic striatal neurotransmission measured ex vivo

AU - Schoffelmeer, Anton N.M.

AU - Nestby, Patrizia

AU - Tjon, Guno H.K.

AU - Wardeh, George

AU - De Vries, Taco J.

AU - Vanderschuren, Louk J.M.J.

AU - Mulder, Arie H.

PY - 1995/11/24

Y1 - 1995/11/24

N2 - Considering the long-lasting neuroadaptations that occur in the brain after exposure to drugs of abuse, we found that the facilitatory effect of an EC50 concentration (0.1 μM) of the acetylcholinesterase inhibitor physostigmine, unlike that of the muscarinic receptor agonist oxotremorine, on K+-induced [3H]dopamine release from rat striatal slices was enhanced about 2-fold 1 month after cessation of intermittent morphine treatment. Similarly, the inhibitory effect of physostigmine on K+-induced [14C]acetylcholine release from the slices was enhanced subsequent to morphine treatment, whereas that of oxotremorine appeared to be unchanged. Therefore, intermittent morphine administration may cause a very long-lasting increase of muscarinic receptor activation by released endogenous acetylcholine in rat striatum, which may play a pivotal role in the enduring character of stimulus hyperresponsiveness after exposure to drugs of abuse.

AB - Considering the long-lasting neuroadaptations that occur in the brain after exposure to drugs of abuse, we found that the facilitatory effect of an EC50 concentration (0.1 μM) of the acetylcholinesterase inhibitor physostigmine, unlike that of the muscarinic receptor agonist oxotremorine, on K+-induced [3H]dopamine release from rat striatal slices was enhanced about 2-fold 1 month after cessation of intermittent morphine treatment. Similarly, the inhibitory effect of physostigmine on K+-induced [14C]acetylcholine release from the slices was enhanced subsequent to morphine treatment, whereas that of oxotremorine appeared to be unchanged. Therefore, intermittent morphine administration may cause a very long-lasting increase of muscarinic receptor activation by released endogenous acetylcholine in rat striatum, which may play a pivotal role in the enduring character of stimulus hyperresponsiveness after exposure to drugs of abuse.

KW - Acetylcholine

KW - Morphine

KW - Muscarinic receptor

KW - Striatum

UR - http://www.scopus.com/inward/record.url?scp=0028874548&partnerID=8YFLogxK

U2 - 10.1016/0014-2999(95)00588-7

DO - 10.1016/0014-2999(95)00588-7

M3 - Article

VL - 286

SP - 311

EP - 314

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 3

ER -